Thyroid Disease | Local Triamcinolone Injection in Active Thyroid Orbitopathy
Thyroid Disease research study
What is the primary objective of this study?
Comparing the effectiveness of subconjunctival and peribulbar Triamcinolone injection to systemic Steroid therapy for patients with active thyroid orbitopathy.
Who is eligible to participate?
Inclusion Criteria: - Age>18 years. - Active thyroid orbitopathy according to clinical activity score>=3. Exclusion Criteria: - Intraorbital or active infections. - Tuberculosis. - Other orbital disease. - Pregnancy. - Compressive optic neuropathy. - Systemic steroid therapy within 6 months of study start.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:TriamcinoloneSubconjunctival and peribulbar, 40 mg/ml, 3 monthly injection
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Start Date: February 2011
Completed Date: February 2013
Primary Outcome: Comparing the effectiveness of subconjunctival and peribulbar Triamcinolone injection to systemic Steroid therapy for patients with active thyroid orbitopathy .
Secondary Outcome: To check if the level of TSH Receptor antibodies are affected by the local injection.
Study sponsors, principal investigator, and references
Principal Investigator: Daniel Briscoe, MD
Lead Sponsor: HaEmek Medical Center, Israel